Company / Cash & Equivalents
Corbus Pharmaceuticals Holdings, Inc. Cash & Equivalents History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$17.0M
FY2022
5-year range
$17.0M / $85.4M
FY2018-FY2022
Trend
-32.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $6M in FY2015 to $85M in FY2020.
Based on SEC 10-K filings.
$17M in FY2022 with a 5-year CAGR of -22.9%.
Declined from $85M to $17M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -18.8%
- 5-Year CAGR
- -22.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -22.9%, indicating a declining trend.
- In FY2022, cash & equivalents decreased 32.0% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $17.0M | -32.0% |
| FY2021 | $25.0M | -70.7% |
| FY2020 | $85.4M | +169.1% |
| FY2019 | $31.7M | -24.0% |
| FY2018 | $41.7M | -33.2% |
| FY2017 | $62.5M | +317.1% |
| FY2016 | $15.0M | +139.4% |
| FY2015 | $6.3M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026